INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41401, 24997, 'Clopidogrel', 'Kidney Diseases', 'Clopidogrel is partially eliminated by the kidney.  Approximately 50% of clopidogrel is excreted in the urine and 45% in the feces.  Plasma concentrations of the inactive metabolite and the degree of platelet inhibition are reduced in patients with severe renal impairment (creatinine clearance of 5-15 mL/min).  However, bleeding times in patients with severe renal impairment did not differ  from those with normal renal function.  No dosage adjustment is recommended for patients with compromised renal function.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41402, 24998, 'Clopidogrel', 'Kidney Diseases', 'Clopidogrel is partially eliminated by the kidney.  Approximately 50% of clopidogrel is excreted in the urine and 45% in the feces.  Plasma concentrations of the inactive metabolite and the degree of platelet inhibition are reduced in patients with severe renal impairment (creatinine clearance of 5-15 mL/min).  However, bleeding times in patients with severe renal impairment did not differ  from those with normal renal function.  No dosage adjustment is recommended for patients with compromised renal function.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41403, 26939, 'Clopidogrel', 'Kidney Diseases', 'Clopidogrel is partially eliminated by the kidney.  Approximately 50% of clopidogrel is excreted in the urine and 45% in the feces.  Plasma concentrations of the inactive metabolite and the degree of platelet inhibition are reduced in patients with severe renal impairment (creatinine clearance of 5-15 mL/min).  However, bleeding times in patients with severe renal impairment did not differ  from those with normal renal function.  No dosage adjustment is recommended for patients with compromised renal function.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41404, 27580, 'Clopidogrel', 'Kidney Diseases', 'Clopidogrel is partially eliminated by the kidney.  Approximately 50% of clopidogrel is excreted in the urine and 45% in the feces.  Plasma concentrations of the inactive metabolite and the degree of platelet inhibition are reduced in patients with severe renal impairment (creatinine clearance of 5-15 mL/min).  However, bleeding times in patients with severe renal impairment did not differ  from those with normal renal function.  No dosage adjustment is recommended for patients with compromised renal function.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41405, 1788, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41406, 1986, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41407, 1989, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41408, 1990, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41409, 1991, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41410, 2003, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41411, 3200, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41412, 3463, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41413, 3465, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41414, 6998, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41415, 7479, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41416, 7480, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41417, 15764, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41418, 15765, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41419, 15766, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41420, 15767, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41421, 15768, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41422, 15775, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41423, 15776, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41424, 16557, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41425, 17341, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41426, 21976, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41427, 21979, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41428, 21980, 'Clotrimazole', 'Liver Diseases', 'Abnormal liver function tests, most often consisting of mild elevations in SGOT levels, have been reported during administration of clotrimazole troches.  The manufacturer recommends periodic assessment of liver function in patients with preexisting hepatic impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41429, 0, 'Coagulation Factor IX Human', 'Heparin induced Thrombocytopenia', 'The brand name products, Kcentra and Bebulin of prothrombin complex, contain heparin; therefore, their use is contraindicated in patients with known heparin-induced thrombocytopenia.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41430, 0, 'Coagulation Factor IX Human', 'Thromboembolism', 'The brand name product, Kcentra of prothrombin complex is contraindicated in patients with disseminated intravascular coagulation (DIC).  Both fatal and non-fatal arterial thromboembolic events (including acute myocardial infarction and arterial thrombosis), and venous thromboembolic events (including pulmonary embolism and venous thrombosis) and disseminated intravascular coagulation have been reported with the use of this product in clinical trials and post marketing surveillance.  Exercise care if using this product in patients with a history of thromboembolic events.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41431, 0, 'Coagulation factor VIIa Recombinant Human', 'Thrombosis', 'Serious arterial and venous thrombotic events have been reported with the use of coagulation factor VIIa.  Patients at an increased risk of thromboembolic complications may include those with a history of coronary heart disease, liver disease, disseminated intravascular coagulation, post-operative immobilizations, elderly patients, and neonates.  It is recommended to exercise caution when administering coagulation factor VIIa to patients at risk and the potential benefit of treatment should be weighed against the risk of these complications.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41432, 0, 'Coagulation factor VIIa Recombinant Human', 'Hypersensitivity', 'Hypersensitivity reactions, including anaphylaxis, can occur with coagulation factor VIIa.  Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions.  Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41433, 2822, 'Clozapine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41434, 2823, 'Clozapine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41435, 2824, 'Clozapine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41436, 2825, 'Clozapine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41437, 2826, 'Clozapine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41438, 2828, 'Clozapine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41439, 7201, 'Clozapine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41440, 21703, 'Clozapine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41441, 22439, 'Clozapine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41442, 25683, 'Clozapine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41443, 26611, 'Clozapine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41444, 26612, 'Clozapine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41445, 29811, 'Clozapine', 'Dementia', 'Older patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; although the causes were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.  A causal relationship with antipsychotic use has not been established.  In controlled trials in older patients with dementia-related psychosis, patients randomized to risperidone, aripiprazole, and olanzapine had higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, compared to patients treated with placebo.  These agents are not approved for the treatment of patients with dementia-related psychosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41446, 2822, 'Clozapine', 'Agranulocytosis', 'The use of clozapine is contraindicated in patients with myeloproliferative disorders, preexisting bone marrow depression, or a history of clozapine-induced agranulocytosis or severe granulocytopenia.  Clozapine therapy is associated with the development of agranulocytosis, defined as an absolute neutrophil count (ANC) below 500/mm3.  The cumulative incidence is estimated at 1% to 2% after one year of use.  The onset is generally between 4 to 16 weeks following initiation of therapy, and it is usually reversible if detected early and the drug discontinued promptly.  All patients should have a white blood cell (WBC) count prior to initiating therapy, and clozapine should not be administered if baseline WBC count is less than 3500/mm3.  WBC counts and differential should be monitored closely during therapy and for 4 weeks after end of therapy according to product labeling.  Also, patients should be advised to immediately report signs of infection such as fever, sore throat, malaise, lethargy, and flu-like symptoms.  Individuals who develop clozapine-induced agranulocytosis or severe granulocytopenia (WBC count < 2000/mm3 or ANC < 1000/mm3) should not be rechallenged following recovery, since the condition may recur, often with a shorter latency on reexposure.  If continued neuroleptic therapy is necessary, other agents may be used with little apparent risk of cross-sensitivity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41447, 2823, 'Clozapine', 'Agranulocytosis', 'The use of clozapine is contraindicated in patients with myeloproliferative disorders, preexisting bone marrow depression, or a history of clozapine-induced agranulocytosis or severe granulocytopenia.  Clozapine therapy is associated with the development of agranulocytosis, defined as an absolute neutrophil count (ANC) below 500/mm3.  The cumulative incidence is estimated at 1% to 2% after one year of use.  The onset is generally between 4 to 16 weeks following initiation of therapy, and it is usually reversible if detected early and the drug discontinued promptly.  All patients should have a white blood cell (WBC) count prior to initiating therapy, and clozapine should not be administered if baseline WBC count is less than 3500/mm3.  WBC counts and differential should be monitored closely during therapy and for 4 weeks after end of therapy according to product labeling.  Also, patients should be advised to immediately report signs of infection such as fever, sore throat, malaise, lethargy, and flu-like symptoms.  Individuals who develop clozapine-induced agranulocytosis or severe granulocytopenia (WBC count < 2000/mm3 or ANC < 1000/mm3) should not be rechallenged following recovery, since the condition may recur, often with a shorter latency on reexposure.  If continued neuroleptic therapy is necessary, other agents may be used with little apparent risk of cross-sensitivity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41448, 2824, 'Clozapine', 'Agranulocytosis', 'The use of clozapine is contraindicated in patients with myeloproliferative disorders, preexisting bone marrow depression, or a history of clozapine-induced agranulocytosis or severe granulocytopenia.  Clozapine therapy is associated with the development of agranulocytosis, defined as an absolute neutrophil count (ANC) below 500/mm3.  The cumulative incidence is estimated at 1% to 2% after one year of use.  The onset is generally between 4 to 16 weeks following initiation of therapy, and it is usually reversible if detected early and the drug discontinued promptly.  All patients should have a white blood cell (WBC) count prior to initiating therapy, and clozapine should not be administered if baseline WBC count is less than 3500/mm3.  WBC counts and differential should be monitored closely during therapy and for 4 weeks after end of therapy according to product labeling.  Also, patients should be advised to immediately report signs of infection such as fever, sore throat, malaise, lethargy, and flu-like symptoms.  Individuals who develop clozapine-induced agranulocytosis or severe granulocytopenia (WBC count < 2000/mm3 or ANC < 1000/mm3) should not be rechallenged following recovery, since the condition may recur, often with a shorter latency on reexposure.  If continued neuroleptic therapy is necessary, other agents may be used with little apparent risk of cross-sensitivity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41449, 2825, 'Clozapine', 'Agranulocytosis', 'The use of clozapine is contraindicated in patients with myeloproliferative disorders, preexisting bone marrow depression, or a history of clozapine-induced agranulocytosis or severe granulocytopenia.  Clozapine therapy is associated with the development of agranulocytosis, defined as an absolute neutrophil count (ANC) below 500/mm3.  The cumulative incidence is estimated at 1% to 2% after one year of use.  The onset is generally between 4 to 16 weeks following initiation of therapy, and it is usually reversible if detected early and the drug discontinued promptly.  All patients should have a white blood cell (WBC) count prior to initiating therapy, and clozapine should not be administered if baseline WBC count is less than 3500/mm3.  WBC counts and differential should be monitored closely during therapy and for 4 weeks after end of therapy according to product labeling.  Also, patients should be advised to immediately report signs of infection such as fever, sore throat, malaise, lethargy, and flu-like symptoms.  Individuals who develop clozapine-induced agranulocytosis or severe granulocytopenia (WBC count < 2000/mm3 or ANC < 1000/mm3) should not be rechallenged following recovery, since the condition may recur, often with a shorter latency on reexposure.  If continued neuroleptic therapy is necessary, other agents may be used with little apparent risk of cross-sensitivity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41450, 2826, 'Clozapine', 'Agranulocytosis', 'The use of clozapine is contraindicated in patients with myeloproliferative disorders, preexisting bone marrow depression, or a history of clozapine-induced agranulocytosis or severe granulocytopenia.  Clozapine therapy is associated with the development of agranulocytosis, defined as an absolute neutrophil count (ANC) below 500/mm3.  The cumulative incidence is estimated at 1% to 2% after one year of use.  The onset is generally between 4 to 16 weeks following initiation of therapy, and it is usually reversible if detected early and the drug discontinued promptly.  All patients should have a white blood cell (WBC) count prior to initiating therapy, and clozapine should not be administered if baseline WBC count is less than 3500/mm3.  WBC counts and differential should be monitored closely during therapy and for 4 weeks after end of therapy according to product labeling.  Also, patients should be advised to immediately report signs of infection such as fever, sore throat, malaise, lethargy, and flu-like symptoms.  Individuals who develop clozapine-induced agranulocytosis or severe granulocytopenia (WBC count < 2000/mm3 or ANC < 1000/mm3) should not be rechallenged following recovery, since the condition may recur, often with a shorter latency on reexposure.  If continued neuroleptic therapy is necessary, other agents may be used with little apparent risk of cross-sensitivity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41451, 2828, 'Clozapine', 'Agranulocytosis', 'The use of clozapine is contraindicated in patients with myeloproliferative disorders, preexisting bone marrow depression, or a history of clozapine-induced agranulocytosis or severe granulocytopenia.  Clozapine therapy is associated with the development of agranulocytosis, defined as an absolute neutrophil count (ANC) below 500/mm3.  The cumulative incidence is estimated at 1% to 2% after one year of use.  The onset is generally between 4 to 16 weeks following initiation of therapy, and it is usually reversible if detected early and the drug discontinued promptly.  All patients should have a white blood cell (WBC) count prior to initiating therapy, and clozapine should not be administered if baseline WBC count is less than 3500/mm3.  WBC counts and differential should be monitored closely during therapy and for 4 weeks after end of therapy according to product labeling.  Also, patients should be advised to immediately report signs of infection such as fever, sore throat, malaise, lethargy, and flu-like symptoms.  Individuals who develop clozapine-induced agranulocytosis or severe granulocytopenia (WBC count < 2000/mm3 or ANC < 1000/mm3) should not be rechallenged following recovery, since the condition may recur, often with a shorter latency on reexposure.  If continued neuroleptic therapy is necessary, other agents may be used with little apparent risk of cross-sensitivity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41452, 7201, 'Clozapine', 'Agranulocytosis', 'The use of clozapine is contraindicated in patients with myeloproliferative disorders, preexisting bone marrow depression, or a history of clozapine-induced agranulocytosis or severe granulocytopenia.  Clozapine therapy is associated with the development of agranulocytosis, defined as an absolute neutrophil count (ANC) below 500/mm3.  The cumulative incidence is estimated at 1% to 2% after one year of use.  The onset is generally between 4 to 16 weeks following initiation of therapy, and it is usually reversible if detected early and the drug discontinued promptly.  All patients should have a white blood cell (WBC) count prior to initiating therapy, and clozapine should not be administered if baseline WBC count is less than 3500/mm3.  WBC counts and differential should be monitored closely during therapy and for 4 weeks after end of therapy according to product labeling.  Also, patients should be advised to immediately report signs of infection such as fever, sore throat, malaise, lethargy, and flu-like symptoms.  Individuals who develop clozapine-induced agranulocytosis or severe granulocytopenia (WBC count < 2000/mm3 or ANC < 1000/mm3) should not be rechallenged following recovery, since the condition may recur, often with a shorter latency on reexposure.  If continued neuroleptic therapy is necessary, other agents may be used with little apparent risk of cross-sensitivity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41453, 21703, 'Clozapine', 'Agranulocytosis', 'The use of clozapine is contraindicated in patients with myeloproliferative disorders, preexisting bone marrow depression, or a history of clozapine-induced agranulocytosis or severe granulocytopenia.  Clozapine therapy is associated with the development of agranulocytosis, defined as an absolute neutrophil count (ANC) below 500/mm3.  The cumulative incidence is estimated at 1% to 2% after one year of use.  The onset is generally between 4 to 16 weeks following initiation of therapy, and it is usually reversible if detected early and the drug discontinued promptly.  All patients should have a white blood cell (WBC) count prior to initiating therapy, and clozapine should not be administered if baseline WBC count is less than 3500/mm3.  WBC counts and differential should be monitored closely during therapy and for 4 weeks after end of therapy according to product labeling.  Also, patients should be advised to immediately report signs of infection such as fever, sore throat, malaise, lethargy, and flu-like symptoms.  Individuals who develop clozapine-induced agranulocytosis or severe granulocytopenia (WBC count < 2000/mm3 or ANC < 1000/mm3) should not be rechallenged following recovery, since the condition may recur, often with a shorter latency on reexposure.  If continued neuroleptic therapy is necessary, other agents may be used with little apparent risk of cross-sensitivity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41454, 22439, 'Clozapine', 'Agranulocytosis', 'The use of clozapine is contraindicated in patients with myeloproliferative disorders, preexisting bone marrow depression, or a history of clozapine-induced agranulocytosis or severe granulocytopenia.  Clozapine therapy is associated with the development of agranulocytosis, defined as an absolute neutrophil count (ANC) below 500/mm3.  The cumulative incidence is estimated at 1% to 2% after one year of use.  The onset is generally between 4 to 16 weeks following initiation of therapy, and it is usually reversible if detected early and the drug discontinued promptly.  All patients should have a white blood cell (WBC) count prior to initiating therapy, and clozapine should not be administered if baseline WBC count is less than 3500/mm3.  WBC counts and differential should be monitored closely during therapy and for 4 weeks after end of therapy according to product labeling.  Also, patients should be advised to immediately report signs of infection such as fever, sore throat, malaise, lethargy, and flu-like symptoms.  Individuals who develop clozapine-induced agranulocytosis or severe granulocytopenia (WBC count < 2000/mm3 or ANC < 1000/mm3) should not be rechallenged following recovery, since the condition may recur, often with a shorter latency on reexposure.  If continued neuroleptic therapy is necessary, other agents may be used with little apparent risk of cross-sensitivity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41455, 25683, 'Clozapine', 'Agranulocytosis', 'The use of clozapine is contraindicated in patients with myeloproliferative disorders, preexisting bone marrow depression, or a history of clozapine-induced agranulocytosis or severe granulocytopenia.  Clozapine therapy is associated with the development of agranulocytosis, defined as an absolute neutrophil count (ANC) below 500/mm3.  The cumulative incidence is estimated at 1% to 2% after one year of use.  The onset is generally between 4 to 16 weeks following initiation of therapy, and it is usually reversible if detected early and the drug discontinued promptly.  All patients should have a white blood cell (WBC) count prior to initiating therapy, and clozapine should not be administered if baseline WBC count is less than 3500/mm3.  WBC counts and differential should be monitored closely during therapy and for 4 weeks after end of therapy according to product labeling.  Also, patients should be advised to immediately report signs of infection such as fever, sore throat, malaise, lethargy, and flu-like symptoms.  Individuals who develop clozapine-induced agranulocytosis or severe granulocytopenia (WBC count < 2000/mm3 or ANC < 1000/mm3) should not be rechallenged following recovery, since the condition may recur, often with a shorter latency on reexposure.  If continued neuroleptic therapy is necessary, other agents may be used with little apparent risk of cross-sensitivity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41456, 26611, 'Clozapine', 'Agranulocytosis', 'The use of clozapine is contraindicated in patients with myeloproliferative disorders, preexisting bone marrow depression, or a history of clozapine-induced agranulocytosis or severe granulocytopenia.  Clozapine therapy is associated with the development of agranulocytosis, defined as an absolute neutrophil count (ANC) below 500/mm3.  The cumulative incidence is estimated at 1% to 2% after one year of use.  The onset is generally between 4 to 16 weeks following initiation of therapy, and it is usually reversible if detected early and the drug discontinued promptly.  All patients should have a white blood cell (WBC) count prior to initiating therapy, and clozapine should not be administered if baseline WBC count is less than 3500/mm3.  WBC counts and differential should be monitored closely during therapy and for 4 weeks after end of therapy according to product labeling.  Also, patients should be advised to immediately report signs of infection such as fever, sore throat, malaise, lethargy, and flu-like symptoms.  Individuals who develop clozapine-induced agranulocytosis or severe granulocytopenia (WBC count < 2000/mm3 or ANC < 1000/mm3) should not be rechallenged following recovery, since the condition may recur, often with a shorter latency on reexposure.  If continued neuroleptic therapy is necessary, other agents may be used with little apparent risk of cross-sensitivity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41457, 26612, 'Clozapine', 'Agranulocytosis', 'The use of clozapine is contraindicated in patients with myeloproliferative disorders, preexisting bone marrow depression, or a history of clozapine-induced agranulocytosis or severe granulocytopenia.  Clozapine therapy is associated with the development of agranulocytosis, defined as an absolute neutrophil count (ANC) below 500/mm3.  The cumulative incidence is estimated at 1% to 2% after one year of use.  The onset is generally between 4 to 16 weeks following initiation of therapy, and it is usually reversible if detected early and the drug discontinued promptly.  All patients should have a white blood cell (WBC) count prior to initiating therapy, and clozapine should not be administered if baseline WBC count is less than 3500/mm3.  WBC counts and differential should be monitored closely during therapy and for 4 weeks after end of therapy according to product labeling.  Also, patients should be advised to immediately report signs of infection such as fever, sore throat, malaise, lethargy, and flu-like symptoms.  Individuals who develop clozapine-induced agranulocytosis or severe granulocytopenia (WBC count < 2000/mm3 or ANC < 1000/mm3) should not be rechallenged following recovery, since the condition may recur, often with a shorter latency on reexposure.  If continued neuroleptic therapy is necessary, other agents may be used with little apparent risk of cross-sensitivity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41458, 29811, 'Clozapine', 'Agranulocytosis', 'The use of clozapine is contraindicated in patients with myeloproliferative disorders, preexisting bone marrow depression, or a history of clozapine-induced agranulocytosis or severe granulocytopenia.  Clozapine therapy is associated with the development of agranulocytosis, defined as an absolute neutrophil count (ANC) below 500/mm3.  The cumulative incidence is estimated at 1% to 2% after one year of use.  The onset is generally between 4 to 16 weeks following initiation of therapy, and it is usually reversible if detected early and the drug discontinued promptly.  All patients should have a white blood cell (WBC) count prior to initiating therapy, and clozapine should not be administered if baseline WBC count is less than 3500/mm3.  WBC counts and differential should be monitored closely during therapy and for 4 weeks after end of therapy according to product labeling.  Also, patients should be advised to immediately report signs of infection such as fever, sore throat, malaise, lethargy, and flu-like symptoms.  Individuals who develop clozapine-induced agranulocytosis or severe granulocytopenia (WBC count < 2000/mm3 or ANC < 1000/mm3) should not be rechallenged following recovery, since the condition may recur, often with a shorter latency on reexposure.  If continued neuroleptic therapy is necessary, other agents may be used with little apparent risk of cross-sensitivity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41459, 2822, 'Clozapine', 'Anticholinergic Syndrome', 'Neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Clozapine use has been associated with impairment of intestinal peristalsis ranging from constipation to intestinal obstruction, fecal impaction, and paralytic ileus.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41460, 2823, 'Clozapine', 'Anticholinergic Syndrome', 'Neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Clozapine use has been associated with impairment of intestinal peristalsis ranging from constipation to intestinal obstruction, fecal impaction, and paralytic ileus.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41461, 2824, 'Clozapine', 'Anticholinergic Syndrome', 'Neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Clozapine use has been associated with impairment of intestinal peristalsis ranging from constipation to intestinal obstruction, fecal impaction, and paralytic ileus.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41462, 2825, 'Clozapine', 'Anticholinergic Syndrome', 'Neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Clozapine use has been associated with impairment of intestinal peristalsis ranging from constipation to intestinal obstruction, fecal impaction, and paralytic ileus.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41463, 2826, 'Clozapine', 'Anticholinergic Syndrome', 'Neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Clozapine use has been associated with impairment of intestinal peristalsis ranging from constipation to intestinal obstruction, fecal impaction, and paralytic ileus.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41464, 2828, 'Clozapine', 'Anticholinergic Syndrome', 'Neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Clozapine use has been associated with impairment of intestinal peristalsis ranging from constipation to intestinal obstruction, fecal impaction, and paralytic ileus.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41465, 7201, 'Clozapine', 'Anticholinergic Syndrome', 'Neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Clozapine use has been associated with impairment of intestinal peristalsis ranging from constipation to intestinal obstruction, fecal impaction, and paralytic ileus.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41466, 21703, 'Clozapine', 'Anticholinergic Syndrome', 'Neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Clozapine use has been associated with impairment of intestinal peristalsis ranging from constipation to intestinal obstruction, fecal impaction, and paralytic ileus.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41467, 22439, 'Clozapine', 'Anticholinergic Syndrome', 'Neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Clozapine use has been associated with impairment of intestinal peristalsis ranging from constipation to intestinal obstruction, fecal impaction, and paralytic ileus.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41468, 25683, 'Clozapine', 'Anticholinergic Syndrome', 'Neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Clozapine use has been associated with impairment of intestinal peristalsis ranging from constipation to intestinal obstruction, fecal impaction, and paralytic ileus.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41469, 26611, 'Clozapine', 'Anticholinergic Syndrome', 'Neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Clozapine use has been associated with impairment of intestinal peristalsis ranging from constipation to intestinal obstruction, fecal impaction, and paralytic ileus.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41470, 26612, 'Clozapine', 'Anticholinergic Syndrome', 'Neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Clozapine use has been associated with impairment of intestinal peristalsis ranging from constipation to intestinal obstruction, fecal impaction, and paralytic ileus.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41471, 29811, 'Clozapine', 'Anticholinergic Syndrome', 'Neuroleptic agents have anticholinergic activity, to which elderly patients are particularly sensitive.  Clozapine and low-potency agents such as chlorpromazine and thioridazine tend to exhibit greater anticholinergic effects than other agents in the class.  Clozapine use has been associated with impairment of intestinal peristalsis ranging from constipation to intestinal obstruction, fecal impaction, and paralytic ileus.  Therapy with neuroleptic agents should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41472, 2822, 'Clozapine', 'Hepatitis', 'Hepatitis has been reported in association with the use of clozapine, both in patients with and without underlying liver function abnormalities.  Therapy with clozapine should be administered cautiously in patients with preexisting liver disease.  The drug should be discontinued if clinically significant elevations of liver function tests or symptoms of jaundice occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41473, 2823, 'Clozapine', 'Hepatitis', 'Hepatitis has been reported in association with the use of clozapine, both in patients with and without underlying liver function abnormalities.  Therapy with clozapine should be administered cautiously in patients with preexisting liver disease.  The drug should be discontinued if clinically significant elevations of liver function tests or symptoms of jaundice occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41474, 2824, 'Clozapine', 'Hepatitis', 'Hepatitis has been reported in association with the use of clozapine, both in patients with and without underlying liver function abnormalities.  Therapy with clozapine should be administered cautiously in patients with preexisting liver disease.  The drug should be discontinued if clinically significant elevations of liver function tests or symptoms of jaundice occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41475, 2825, 'Clozapine', 'Hepatitis', 'Hepatitis has been reported in association with the use of clozapine, both in patients with and without underlying liver function abnormalities.  Therapy with clozapine should be administered cautiously in patients with preexisting liver disease.  The drug should be discontinued if clinically significant elevations of liver function tests or symptoms of jaundice occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41476, 2826, 'Clozapine', 'Hepatitis', 'Hepatitis has been reported in association with the use of clozapine, both in patients with and without underlying liver function abnormalities.  Therapy with clozapine should be administered cautiously in patients with preexisting liver disease.  The drug should be discontinued if clinically significant elevations of liver function tests or symptoms of jaundice occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41477, 2828, 'Clozapine', 'Hepatitis', 'Hepatitis has been reported in association with the use of clozapine, both in patients with and without underlying liver function abnormalities.  Therapy with clozapine should be administered cautiously in patients with preexisting liver disease.  The drug should be discontinued if clinically significant elevations of liver function tests or symptoms of jaundice occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41478, 7201, 'Clozapine', 'Hepatitis', 'Hepatitis has been reported in association with the use of clozapine, both in patients with and without underlying liver function abnormalities.  Therapy with clozapine should be administered cautiously in patients with preexisting liver disease.  The drug should be discontinued if clinically significant elevations of liver function tests or symptoms of jaundice occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41479, 21703, 'Clozapine', 'Hepatitis', 'Hepatitis has been reported in association with the use of clozapine, both in patients with and without underlying liver function abnormalities.  Therapy with clozapine should be administered cautiously in patients with preexisting liver disease.  The drug should be discontinued if clinically significant elevations of liver function tests or symptoms of jaundice occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41480, 22439, 'Clozapine', 'Hepatitis', 'Hepatitis has been reported in association with the use of clozapine, both in patients with and without underlying liver function abnormalities.  Therapy with clozapine should be administered cautiously in patients with preexisting liver disease.  The drug should be discontinued if clinically significant elevations of liver function tests or symptoms of jaundice occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41481, 25683, 'Clozapine', 'Hepatitis', 'Hepatitis has been reported in association with the use of clozapine, both in patients with and without underlying liver function abnormalities.  Therapy with clozapine should be administered cautiously in patients with preexisting liver disease.  The drug should be discontinued if clinically significant elevations of liver function tests or symptoms of jaundice occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41482, 26611, 'Clozapine', 'Hepatitis', 'Hepatitis has been reported in association with the use of clozapine, both in patients with and without underlying liver function abnormalities.  Therapy with clozapine should be administered cautiously in patients with preexisting liver disease.  The drug should be discontinued if clinically significant elevations of liver function tests or symptoms of jaundice occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41483, 26612, 'Clozapine', 'Hepatitis', 'Hepatitis has been reported in association with the use of clozapine, both in patients with and without underlying liver function abnormalities.  Therapy with clozapine should be administered cautiously in patients with preexisting liver disease.  The drug should be discontinued if clinically significant elevations of liver function tests or symptoms of jaundice occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41484, 29811, 'Clozapine', 'Hepatitis', 'Hepatitis has been reported in association with the use of clozapine, both in patients with and without underlying liver function abnormalities.  Therapy with clozapine should be administered cautiously in patients with preexisting liver disease.  The drug should be discontinued if clinically significant elevations of liver function tests or symptoms of jaundice occur.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41485, 2822, 'Clozapine', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41486, 2823, 'Clozapine', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41487, 2824, 'Clozapine', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41488, 2825, 'Clozapine', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41489, 2826, 'Clozapine', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41490, 2828, 'Clozapine', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41491, 7201, 'Clozapine', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41492, 21703, 'Clozapine', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41493, 22439, 'Clozapine', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41494, 25683, 'Clozapine', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41495, 26611, 'Clozapine', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41496, 26612, 'Clozapine', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41497, 29811, 'Clozapine', 'Alcoholic Intoxication', 'The use of neuroleptic agents is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of neuroleptic agents may be additive with those of alcohol.  Severe respiratory depression and respiratory arrest may occur.  Therapy with neuroleptic agents should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41498, 2822, 'Clozapine', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41499, 2823, 'Clozapine', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41500, 2824, 'Clozapine', 'Respiratory Insufficiency', 'The use of neuroleptic agents is contraindicated in comatose patients and patients with severe central nervous system depression.  Neuroleptic agents may potentiate the CNS and respiratory depression in these patients.', '3', '', 'DDInter', 0);
